Antidote's EU Green Light Brightens Pradaxa Sales Outlook
This article was originally published in Scrip
The positive opinion granted by the European Medicines Agency to a reversal agent that is expected to be used very rarely brings Boehringer Ingelheim one step closer to a potential healthy injection of additional sales for its anticoagulant Pradaxa (dabigatran). Datamonitor Healthcare predicts that Pradaxa revenues in the EU could rise by 15% by 2020, should the Pradaxa antidote Praxbind (idarucizumab) be approved this year. This is now expected following the positive recommendation from the EMA's Committee for Medicinal Products for Human Use (CHMP).
You may also be interested in...
GlamorousAI is developing technology to uncover new targets and take on previously intractable disease challenges. Founder Noor Shaker hopes to license a drug to big pharma within the next three years.
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.